TWST Stock Forecast & Price Target

Twist Bioscience is viewed positively because its silicon-based DNA synthesis platform lowers cost and improves throughput, creating a durable competitive advantage in synthetic biology and enabling broader adoption across NGS and DNA synthesis. The company also appears to be entering a multi-year demand inflection from AI-enabled drug discovery, with AI-related orders expected to reach triple-digits % in FY26 at least about $50M versus $25M in FY25, while NGS should still represent a majority of revenues in FY26. Fundamentally, the outlook is supported by conservative FY26 guidance, an estimated $446M in FY26 revenue (+19% y/y), capacity for more than $1B in revenue at Factory of the Future, and improving operating leverage toward Adj. EBITDA breakeven in FQ4.

Twist Bioscience is viewed negatively because it trades at a significant premium to peers while competing in a crowded life sciences tools market where integrated incumbents like Danaher, Agilent, and Roche can pressure pricing through bundled offerings and broad reagent catalogs. Its NGS-driven base business faces risk from slowing momentum, customer concentration, and end-market variability, so any slip in demand or quarterly guidance could undermine confidence in growth durability and the path to profitability. The profitability case also depends on sustained gross margin improvement and disciplined expense control, yet heavier-than-expected investment or market share erosion could delay breakeven and compress the valuation multiple.